Correct Answer: D. Endometrial biopsy
In a postmenopausal or perimenopausal woman (46 years old is likely perimenopausal) presenting with abnormal uterine bleeding and endometrial thickness ≥16 mm on ultrasound, the critical next step is endometrial biopsy. This is the gold standard for ruling out endometrial malignancy, which must be excluded before initiating conservative management. According to Indian guidelines and international consensus (ACOG, FIGO), any postmenopausal woman with abnormal bleeding and endometrial thickness >4–5 mm, or any perimenopausal woman with persistent abnormal bleeding and thickness ≥16 mm, requires tissue diagnosis. Endometrial biopsy is minimally invasive, can be performed in the outpatient setting without anesthesia, has high sensitivity (90–99%) for detecting endometrial cancer and hyperplasia, and provides histological diagnosis to differentiate benign causes (atrophy, polyps, hyperplasia) from malignancy. Only after malignancy is excluded can hormonal therapy or other conservative measures be considered. Hysterectomy is definitive but not the "next best step"—it is reserved for cases where malignancy is confirmed or when conservative measures fail.
Why the other options are wrong
A. HPV testing — HPV testing is relevant for cervical cancer screening, not endometrial pathology. Endometrial cancer is not HPV-associated in the same way cervical cancer is. This is a distractor that confuses cervical and endometrial screening protocols. HPV testing has no role in evaluating abnormal uterine bleeding with thickened endometrium. B. Progesterone therapy — Progesterone therapy (medical management) is appropriate only after malignancy has been excluded by tissue diagnosis. Starting hormonal therapy without ruling out endometrial cancer is dangerous and delays diagnosis of potentially life-threatening pathology. This is a common NBE trap—students may think of hormonal therapy as first-line, but it is contraindicated until biopsy confirms benign disease. C. Hysterectomy — Hysterectomy is a definitive surgical treatment but is not the 'next best step' in the diagnostic algorithm. It is reserved for confirmed malignancy, failed conservative management, or patient choice after benign pathology is confirmed. Performing hysterectomy without tissue diagnosis is overtreatment and violates the principle of stepwise evaluation in abnormal uterine bleeding.
High-Yield Facts
- Endometrial thickness ≥16 mm in a woman with abnormal uterine bleeding mandates tissue diagnosis (biopsy) to exclude malignancy.
- Endometrial biopsy is the gold standard for diagnosis of endometrial cancer, hyperplasia, and other intrauterine pathology; sensitivity 90–99%.
- Postmenopausal bleeding with thickness >4–5 mm or perimenopausal bleeding with thickness ≥16 mm requires biopsy before any medical or surgical intervention.
- Progesterone therapy is contraindicated until malignancy is ruled out; it is used only for benign endometrial hyperplasia without atypia after biopsy confirmation.
- Hysterectomy is definitive but reserved for confirmed malignancy or failed conservative management; it is not the initial diagnostic step.
Mnemonics
THICK ENDOMETRIUM = BIOPSY FIRST When endometrial thickness is abnormal (≥16 mm in perimenopausal, >4–5 mm in postmenopausal) with AUB → Always biopsy first to exclude cancer before treating. Biopsy rules out malignancy; only then consider medical (progesterone) or surgical (hysterectomy) options. AUB ALGORITHM: BIOPSY → DIAGNOSIS → TREATMENT Abnormal Uterine Bleeding with thickened endometrium: (1) Biopsy for tissue diagnosis, (2) Identify pathology (cancer, hyperplasia, polyp, atrophy), (3) Treat accordingly. Never skip step 1.
NBE Trap
NBE pairs "abnormal uterine bleeding" with "progesterone therapy" to lure students into thinking hormonal therapy is first-line. The trap is forgetting that tissue diagnosis must precede treatment in any woman with abnormal bleeding and thickened endometrium, because endometrial cancer must be excluded first.
Clinical Pearl
In Indian clinical practice, many women present late with abnormal bleeding; endometrial biopsy (office-based, no anesthesia required) is the quickest way to rule out endometrial cancer and guide further management. A 46-year-old with heavy bleeding and 16 mm thickness is at risk for both hyperplasia and malignancy—biopsy is non-negotiable before any hormonal or surgical intervention.
_Reference: DC Dutta's Textbook of Gynaecology (6th ed.), Ch. 13 (Abnormal Uterine Bleeding); ACOG Practice Bulletin #128 (Diagnosis of Abnormal Uterine Bleeding in Reproductive-Age Women)_